Skip to main
AYTU

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma Inc. is positioned for favorable growth due to its attractive current valuation, with a raised price target indicating substantial upside potential based on net present value analysis. The company's ongoing development of the EXXUA drug, which has shown significant improvement in depression symptoms without major side effects in extensive clinical trials, presents a strong catalyst for future performance. Additionally, Aytu's diverse portfolio addressing prevalent pediatric conditions and a pipeline targeting rare diseases enhances its revenue-generating capabilities and long-term financial prospects.

Bears say

Aytu BioPharma reported Q1 results showing a revenue decline of 16% year-over-year, amounting to $13.9 million, which fell short of both its projections and market consensus. Despite claims of significant upside potential and future sales estimates, the company's current financial performance indicates a challenging market position that raises concerns about its ability to capitalize on growth prospects. Furthermore, while there are extensive prescriptions for related treatments, the ongoing issues with current therapeutics' side effects suggest substantial unmet needs, which may hinder Aytu BioPharma's ability to establish a competitive edge in this space.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.